- Title
- Depression, anxiety, and stress among people with chronic hepatitis C virus infection and a history of injecting drug use in New South Wales, Australia
- Creator
- Fortier, Emmanuel; Alavi, Maryam; Bath, Nicky; Haber, Paul S.; Dore, Gregory J.; Grebely, Jason; ETHOS Study Group,; Bruneau, Julie; Micallef, Michelle; Perram, Jacinta; Sockalingam, Sanjeev; Dunlop, Adrian J.; Balcomb, Annie C.; Day, Carolyn A.; Treloar, Carla
- Relation
- Funding BodyNHMRCGrant Number568985 http://purl.org/au-research/grants/nhmrc/568985
- Relation
- Journal of Addiction Medicine Vol. 11, Issue 1, p. 10-18
- Publisher Link
- http://dx.doi.org/10.1097/ADM.0000000000000261
- Publisher
- Lippincott Williams & Wilkins
- Resource Type
- journal article
- Date
- 2017
- Description
- Objective: The aims of this study were to assess symptoms of depression, anxiety, and stress and associated sociodemographic factors among people living with chronic hepatitis C virus (HCV) infection with a history of injecting drug use and to assess the association between symptoms of depression, anxiety, or stress and HCV treatment intent, specialist assessment, or treatment uptake. Methods: The Enhancing Treatment for Hepatitis C in Opioid Substitution Settings was an observational cohort study evaluating the provision of HCV assessment and treatment among people with chronic HCV and a history of injecting drug use, recruited from 9 community health centers and opioid substitution therapy (OST) clinics (New South Wales, Australia). Symptoms were assessed using the Depression Anxiety Stress Scales (DASS-21). Analyses were performed using logistic regression. Results: Among 415 participants (mean age 41 years, 71% male), 47%, 52%, and 36% demonstrated moderate to extremely severe symptoms of depression, anxiety, and stress, respectively. In adjusted analyses, depression symptoms were associated with recent injecting drug use [adjusted odds ratio (aOR) 1.63, 95% confidence interval (CI) 1.07-2.49), whereas stress symptoms were associated with unemployment (aOR 2.99, 95% CI 1.09-8.15) and not living with a spouse or other relatives/friends (aOR 1.55, 95% CI 1.01-2.39). Symptoms of depression, anxiety, or stress or having a history of treated mental illness were not independently associated with HCV treatment intent, specialist assessment, or treatment uptake. Conclusions: Findings suggest a need for improved interventions and care regarding mental health among people living with chronic HCV with a history of injecting drug use, but suggest that symptoms of depression, anxiety, and stress should not be immediate contraindications to HCV assessment and treatment.
- Subject
- anxiety; depression; hepatitis C virus; people who inject drugs; stress
- Identifier
- http://hdl.handle.net/1959.13/1392113
- Identifier
- uon:33344
- Identifier
- ISSN:1932-0620
- Language
- eng
- Reviewed
- Hits: 10442
- Visitors: 10765
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|